Related posts

Markets rally to end week, yields calmOil and yields sink, stocks reboundStocks, yields climb, oil flat
Investor Insights

This summary was created by AI, based on 17 opinions in the last 12 months.

Based on the reviews from different experts, the consensus seems to be that the company is facing challenges with its debt and interest rates, as well as changes in management. The distribution cut and potential dividend cuts are also cause for concern. However, there is confidence in the business going forward, and efforts are being made to rework the portfolio and right-size the balance sheet. Overall, the company's valuation has been negatively impacted and it is currently in a difficult spot.

Consensus
Caution
Valuation
Undervalued
Similar
N/A
BUY

Large collection of healthcare real estate around the world. Inflation linked leases (good for income). Sticky tenants with doctors and healthcare. Problem is too much floating debt (higher interest rates). Recently replaced management team. Confident on business going forward. Expecting strength going forward. Book value is around $6-$7/share (trading around $4).  

REAL ESTATE
DON'T BUY

It is effectively a REIT. It is down 50% over the past year, a function of interest rate pressure. They have cut their dividend.

REAL ESTATE
PAST TOP PICK
(A Top Pick Dec 14/23, Down 43%)

Healthcare property business not performing as well as anticipating. Floating rate debt very hard on business with rising interest rates. CEO has since resigned. Would recommend holding going forward. 

REAL ESTATE
SELL

Cut dividend. Healthcare properties around the world. Over-levered in a rising interest rate environment. Valuation imploded. Steer clear. Other distressed real estate ideas out there have more catalysts.

REAL ESTATE
DON'T BUY

In flux. Founder/CEO left. Looking at strategic alternatives, possible asset sales. High leverage. A show-me story. Execution risk to sell assets and fix balance sheet in a difficult market.

REAL ESTATE
DON'T BUY

Over-levered. Properties aren't performing as well. Geographic distribution requires them to be experts globally, which is a problem. CEO resigned, change in management. Whole sector's under stress, low quality gets hit harder.

REAL ESTATE
HOLD

Recent cut in dividend. Not expecting any more dividend cuts going forward. Does not own shares at this time. If already own shares, would recommend keeping. 

REAL ESTATE
DON'T BUY

Messy. Cut dividend by 55%. Good lesson on chasing a too-high dividend yield. 97% occupancy, but not enough to keep them out of financial difficulties. $4B of debt, more than 1/3 at floating rates. Giant "For sale" sign on it. Insider selling in January. Facing tax-loss selling if things don't turn around.

REAL ESTATE
DON'T BUY

Lots of debt, operating in jurisdictions with currency risk. Bought stable, UK and US assets, but got caught offside with variable-rate debt cutting into cashflow. Cut distribution. Execution risk. Sold off, but don't add.

REAL ESTATE
DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

The distribution cut was needed, but of course was fairly large (55%). The asset sales are a good start but challenges remain. The strategic review is only seven weeks old, but reading between the lines it sounds like there has not been huge interest yet. It is hard to endorse this right now. With higher rates and lower assets (from sales), growth will be hard to come by. We might be reluctant to sell it on the first trading day of this news, but we certainly think it can be 'targetted' for elimination from an investor's portfolio and used as a source of cash for other ideas. The stock will likely be in the penalty box for some time for multiple disappointments over the past year, with a business that is supposed to be more reliable and more predictable. We would not see solvency as an issue but it is just hard to like right now. 
Unlock Premium - Try 5i Free

REAL ESTATE
DON'T BUY

Got on the wrong side of managing its debt. Now it's trying to figure out how to service it, with some success. But risk/return is not best way to deploy your capital. Too risky for him.

REAL ESTATE
BUY ON WEAKNESS

Problem with company includes floating rate debt (higher interest rates).
Owns large array of health care real estate assets.
Capital structure and dividend policy not in a good position.
Concerned about potential of dividend cut.


REAL ESTATE
WAIT

Pounded along with a lot of real estate. Quality company. There will be some carnage across real estate, and it's hard to predict the knock-on effects. Be cautious. If you own it, you're not in peril. Otherwise, wait till interest rates have peaked, and you might get it even cheaper.

REAL ESTATE
HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

We would consider results OK. Cash flow per share of 16c did miss estimates of 17c, but revenue of $135M beat estimates of $122M. Payout ratio has risen but on an annual basis was 68% in 2022. Operating income increased, offset by higher rates.  Occupancy is good at 97%, leases are long and many are indexed. The convertible issue, the institutional investor and the planned asset sales should add a lot more financial flexibility. The proof will be in the pudding but the comments we think make the point that management knows that leverage and recession concerns are hurting their valuation. We are not sure the corned has been turned, but are more optimistic than pessimistic, largely because of its already-low valuation. 
Unlock Premium - Try 5i Free

REAL ESTATE
SELL

Heading down and continues to make new lows. Moving opposite to the TSX, which has turned and is heading higher. Lower lows and lower highs, the definition of a downtrend. Sell your losers.

REAL ESTATE
Showing 1 to 15 of 113 entries

NorthWest Health Prop Real Est Inv Trust(NWH.UN-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 10

Total Signals / Votes : 15

Stockchase rating for NorthWest Health Prop Real Est Inv Trust is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

NorthWest Health Prop Real Est Inv Trust(NWH.UN-T) Frequently Asked Questions

What is NorthWest Health Prop Real Est Inv Trust stock symbol?

NorthWest Health Prop Real Est Inv Trust is a Canadian stock, trading under the symbol NWH.UN-T on the Toronto Stock Exchange (NWH.UN-CT). It is usually referred to as TSX:NWH.UN or NWH.UN-T

Is NorthWest Health Prop Real Est Inv Trust a buy or a sell?

In the last year, 15 stock analysts published opinions about NWH.UN-T. 3 analysts recommended to BUY the stock. 10 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for NorthWest Health Prop Real Est Inv Trust.

Is NorthWest Health Prop Real Est Inv Trust a good investment or a top pick?

NorthWest Health Prop Real Est Inv Trust was recommended as a Top Pick by on . Read the latest stock experts ratings for NorthWest Health Prop Real Est Inv Trust.

Why is NorthWest Health Prop Real Est Inv Trust stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is NorthWest Health Prop Real Est Inv Trust worth watching?

15 stock analysts on Stockchase covered NorthWest Health Prop Real Est Inv Trust In the last year. It is a trending stock that is worth watching.

What is NorthWest Health Prop Real Est Inv Trust stock price?

On 2024-02-28, NorthWest Health Prop Real Est Inv Trust (NWH.UN-T) stock closed at a price of $4.07.